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Summary 
Mice immunized against a cancer recognize antigens 
unique to that cancer, but the molecular structures of 
such antigens are unknown. We isolated CD4+ T ceil 
clones recognizing an antigen uniquely expressed on 
the UV-induced tumor 6132A; some clones inhibited 
the growth of tumors bearing the specific antigen. A 
T ceil hybridoma was used to purify this antigen from 
nuclear extracts by RP-HPLC and SDS-PAGE using T 
ceil immunobiot assays. A partial amino acid sequence 
was nearly identical to a sequence in ribosomal protein 
L9. The cDNA sequence of L9 from 6132A PRO ceils 
differed from the normal sequence at one nucieotide; 
this mutation encoded histidine instead of ieucine at 
position 47. A synthetic peptlde containing this muta- 
tion was over lOOO-fold more stimulatory of T cells 
than was the wild-type peptide. These results indicate 
that this unique tumor antigen is derived from a single 
amino acid substitution in a cellular protein. 
introduction 
T lymphocytes from many cancer patients display at least 
rudimentary reactivity against the malignancies of the 
hosts. Recently, several shared tumor antigens recog- 
nized by these T cells or by T cells from mice immunized 
with cancer cells have been identified at the molecular 
level (Van der Bruggen et al., 1991; Van den Eynde et al., 
1991; Brichard et al., 1993; Gaugler et al., 1994; Bakker 
et al., 1994; Kawakami et al., 1994; Mandelboim et al., 
1994). Each of these antigens has also been found in other 
tumors or cell lines similar in origin to the tumor from which 
the antigen was isolated; occasionally, the antigens are 
expressed by cancers from different lineages as well. In 
general, the proteins are known to be identical to their 
counterparts in normal tissues. 
The above findings on shared tumor antigens cannot, 
however, account for the results of experiments that ex- 
plored acquisition of immunity to tumors: immunization of 
animals against tumors usually confers specific immunity 
against that particular tumor and not others, even those 
of the same tissue type induced with the same carcinogen 
(Prehn and Main, 1957; Pasternaketal., 1964; Basombrio, 
1970; Kripke, 1974; for review see Srivastava and Old, 
1966). Such specificity indicates the existence of “unique” 
or individually distinct tumor transplantation antigens, as 
opposed to “shared” or tumor-associated transplantation 
antigens. The diversity of unique tumor antigens is so strik- 
ing that Burnet (1970) has compared it with that of immune 
receptors or histocompatibility antigens. 
Molecular characterization of unique tumor antigens, in 
contrast with that of shared antigens, is still at an early 
stage. It is possible that these unique antigens, which are 
recognized by T cells of animals immunized against can- 
cer cells (Ward et al., 1969; Cohen et al., 1994) can indeed 
arise through somatic mutation of cell proteins. Such a 
protein might become immunogenic after mutation, while 
the host would likely be tolerant of its normal counterpart. 
Some of the mutant proteins known to be present in cancer 
cells, such as mutant Ras and ~53, can be used to induce 
immunity and inhibit tumor growth (Fenton et al., 1993; 
Noguchi et al., 1994). However, when animals are immu- 
nized with tumor cells expressing mutant Ras or p53 pro- 
teins, the T cells harvested from these animals do not 
recognize Ras or p53 (Carbone et al., 1991; Noguchi et 
al., 1994) but instead recognize other unknown antigens. 
Thus, mutant Ras and mutant p53 proteins are not the 
unique tumor antigens responsible for the strong immunity 
induced by immunization with tumor cells. 
Most investigators have used CD6+ cytolytic T lympho- 
cytes (CTL) to define tumor antigens, because these cells 
are required for the rejection of most experimental cancers 
by naive mice (Udono et al., 1969; Ward et al., 1990) and 
can be used to transfer immunity from immune to naive 
mice (Rosenstein et al., 1964; Chou and Shu, 1967). How- 
ever, immunity to cancer has also been transferred to new 
hosts using only CD4+ T cells from immune animals 
(Greenberg et al., 1961; Fujiwara et al., 1964; Ozawa et 
al., 1967). In two models, one using a plasmacytoma and 
one a Friend virus-induced leukemia, immune CD4+ cells 
appear to have caused rejection of malignant cells even 
in hosts presumably lacking CD6+ cells (Fujiwara et al., 
1964; Greenberg et al., 1965). CD4+ T cell lines and clones 
reacting with unique and shared tumor antigens in vitro 
have been isolated (Cohen et al., 1994; Rohrer et al., 1994; 
Topalian et al., 1994), but the effects of these T cells in 
vivo and the identities of the recognized unique antigens 
are unknown. We have begun to identify the molecular 
nature and genetic origins of unique tumor-specific anti- 
gens recognized by T cells of mice immunized with tumor 
cells. In this study, we have used CD4+ T cell clones iso- 
lated from mice immunized against an ultraviolet light 
(U&induced cancer to identify, using a novel approach, 
the recognized unique antigen as ribosomal protein L9 
containing a point mutation. 
Results 
Isolation of CD4+ T Ceil Clones and a Hybridoma 
Recognizing a Unique Tumor Antigen 
The method used to isolate CD4+ clones was adapted from 
one used to obtain cells recognizing soluble antigens (Ga- 
jewski et al., 1969). Mice were immunized with 6132A PRO 
tumor cells emulsified in complete Freund’s adjuvant 
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Table 1. Response of CDQT Cell Clones to Tumor Antigens 
Clone 
c45-13 
c47-9 
c47-10 
c47-150 
c47-17 
C47-21 
c417-5 
IL-2 IL-4 IFNy TNF/LT 
380 <3 97000 110 
42 <3 22000 110 
240 <3 100000 250 
10 <3 9700 ND 
180 <3 81000 90 
<0.8 210 <80 12 
210 <3 38000 140 
Antigen cpm 2 SEM 
None 510 f 72 
PRC4L 43822 e 2182 
8138 732 f 75 
8132A PRO 478 2 48 
None 3835 2 205 
PR04L 3274 2 325 
81398 2801 f 204 
8132A PRO 58145 f 1242 
None 3757 * 885 
PR04L 3378 f 213 
81398 3218 k 224 
8132A PRO 41131 f 429 
None 471 f 83 
PR04L 384 f 33 
8138 490 f 30 
8132A PRO 11959 f 1925 
None 1104 + 30 
TR-PRO 958 f 8 
8132A PRO 108274 f 4300 
None 531 f 48 
TR-PRO 573 f 8 
8132A PRO 7502 -c 229 
None 2035 f 01 
PRO4L 2017 f 23 
81396 2387 f 523 
8132A PRO 48853 + 1883 
Thymidine incorporation assay (columns 2-4). T cell clones were incubated with syngeneic spleen cells and tumor cell extracts at a concentration 
of 3 x lo5 cell equivalents per ml. 13H]thymidine was added at about 24 hr, and the cultures were harvested at 40-48 hr. The numbers are the 
mean counts per minute @pm) f standard errors @EM) of triplicate cultures in representative experiments. Cytokine assays (columns 5-8). T 
cell clones were cultured for 48 hr in wells coated with anti-CD3 MAb 2Cll. Supernatants were tested for the presence of IL-2 and IL-4 by stimulation 
of CTLL-2 cells, of ylFN by ELISA, and of TNFlLT by cytolysis/cytostasis of 1591 RE3.5 cells. The numbers are U per ml, rounded to two significant 
figures, calculated by comparison to assays with recombinant cytokines in representative experiments. ND, not determined. 
(CFA). Cells from the draining lymph nodes were restimu- 
lated with tumor cell lysates in vitro and then cloned by 
limiting dilution (see Experimental Procedures). We ob- 
tained clones that synthesized DNA in the presence of 
lysates of 6132A PRO cells but not lysates of other UV- 
induced skin tumors that had also originated in C3H mice 
(Table 1). When stimulated by anti-CD3 antibodies, most 
of the clones secreted interleukin-2 (IL-2) interferon-y 
(IFNy), and tumor necrosis factor (TNF) or lymphotoxin 
(LT), and one secreted IL-4 (Table 1). These clones thus 
appeared to fall into the categories of Thl and Th2 cells, 
respectively (Mosmann et al., 1966). By analogous proce- 
dures, we isolated aTh1 clone recognizing the 1591 tumor 
and its progressor variant PR04L. All clones expressed 
CD4 by immunofluorescent staining and flow cytometry. 
Among the 6132Aspecific clones, at least three different 
T cell receptors (TCR) were represented, as 5 of 6 clones 
were stained with antibodies binding Vp6 (C47-9, C47-17, 
C47-21) or Vj314 (C47-10, C47-158) whereas C417-5 was 
not stained with either antibody. Stimulation of clones was 
found repeatedly using lysates of cells that appeared to 
be free of mycoplasma by fluorescent staining, indicating 
that mycoplasma was unlikely to be the source of antigen. 
Because a T cell hybridoma would be easier to maintain 
and prepare for assays than a T cell clone, and therefore 
would be more useful for assessing the purification of a 
tumor antigen, we fused the 6132A-specific clone C47-9 
with BW5147. Hybridoma 479H-60 secreted IL-2 in re- 
sponse to small amounts of lysates of 6132A PRO; it did 
not secrete detectable IL-2 in response to lysates of eight 
other UV-induced tumors, nor to lysates of autologous fi- 
broblasts (Figure 1). These results suggested that the anti- 
gen recognized by this hybridoma might be uniquely ex- 
pressed by 6132A PRO as well as by 6132A, the parental 
regressor tumor from which the more aggressive variant 
arose (data not shown). The lack of stimulation by autolo- 
gous fibroblasts or by 61328, a second UV-induced skin 
tumor that arose independently at a different site in the 
same mouse as did 6132A, suggested that the antigen 
was not encoded by a germline mutation particular to the 
mouse of tumor origin. 
Determination of Requirements for Processing 
and Presentation 
Conventional antigens recognized by CD4+ cells are pep- 
tides of 12-24 aa associated with major histocompatibility 
complex (MHC) class II molecules (Rudensky et al., 1991; 
Hunt et al., 1992; Chicz et al., 1992). At least two other 
types of antigen, however, could be produced by cancer 
cells. Superantigens are proteins that bind to MHC class 
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Figure 1. Unique Specificity of a T Cell Hybridoma for an Antigen on 
6132A PRO Cells 
T cell hybridoma 479H-60 was incubated with C3H spleen cells and 
lysates of various cells, and IL-2 in supernatants was measured by 
stimulation of CTLL-2 cells. Left: 6132A PRO (closed circle), 6136 
(open circle), 61398 PRO (closed triangle), 4102 PRO (open square), 
1591 PR04L (open triangle). Middle: 6132A PRO (closed circle), 
6134A PRO (open circle), 6132 HLF (closed triangle; nontransformed 
autologousfibroblasts). Right: 6132A PRO(closed circle), 61328 (open 
circle; autologous second tumor), AG164A (closed triangle), 6130 
(open square). Each point represents the mean of duplicate (left) or 
triplicate (middle and right) wells, with error bars showing the range 
or SEM, respectively. The means of wells without antigen are shown 
as dotted lines. Errors less than 0.02 are not shown. 
II molecules outside of the peptide-binding groove and to 
particular TCR Vp structures (for review see Herman et al., 
1991); in this way, they can stimulate a large percentage 
of the lymphocytes of an animal. Modified MHC class II 
molecules, associated with a variety of peptides, could 
similarly stimulate many CD4+ cells in a manner analogous 
to an allogeneic mixed lymphocyte reaction. 
We investigated the MHC class II restriction of 6132A- 
specific clones in three ways. First, DNA synthesis by all 
of the 6132A-specific clones shown in Table 1 was com- 
pletely blocked by monoclonal antibody (MAb) 14-4-48, 
which binds I-Ek, but not by MAb 10-2-16, which binds 
I-Ak (Figure 2A). Second, the T cell hybridoma 479H-60 
recognized antigen presented by cells transfected with 
I-Ek but not by cells transfected with I-Ak (Figure 28). Third, 
transfection of cDNAs encoding I-Ek into 6132A PRO cells 
sensitized these cells for lysis by clone C47-9 (Figure 2C). 
All of the 6132A-specific Thl clones had previously been 
found to be cytolytic toward I-Ak+/l-Ek+ cells incubated with 
lysates of 6132A PRO, with an efficiency similar to or 
higher than that shown in Figure2C. TheThP clone C47-21 
was not cytolytic (data not shown). 
Conventional antigens, unlike superantigens, require in- 
tracellular processing to be recognized in association with 
MHC class II. The lysosomotropic drug chloroquine blocks 
this process(Allen and Unanue, 1964). We found that chlo- 
roquine also blocked presentation of 6132A antigen (Fig- 
ure 3). In addition, 6132A antigen was not presented by 
BALBlc (H-2d) spleen cells (data not shown); superanti- 
gens usually can bind to multiple MHC class II alleles (De- 
Kruyff et al., 1966; Fleischer and Schrezenmeier, 1966). 
Together, these results suggested that the 6132A antigen 
was a processed peptide associated with I-Ek. 
Inhibition of Tumor Growth by Thl Clones 
The 6132A PRO tumor grows progressively in only lO%- 
60% of immunocompetent mice receiving tumor trans- 
plants (Ward et al., 1990; data not shown). It was therefore 
impractical to use CD4+ clones to try to inhibit tumor growth 
in normal mice, because of the large numbers of mice 
needed to see significant differences between groups. 
However, in mice with severe combined immunodefi- 
ciency (SCID), a genetic defect that results in the absence 
of T and B lymphocytes, this tumor always grows progres- 
sively, even in mice inoculated with low numbers of cells. 
One clone recognizing 6132A (C47-17) and one recogniz- 
ing the 1591 lineage (C45-13) each inhibited, in C3H SCID 
mice (Figure 4), the growth of the tumor that it recognized 
in vitro. As measured by immunofluorescent staining and 
flow cytometry, neither tumor cell line expressed detect- 
able I-Ak or I-Ek when cultured with or without IFNy. Al- 
though the 6132A-specific clone appeared to be unable 
to cause complete rejection, its inhibition of tumor growth 
in mice lacking CD6+Tcells is remarkable, because 6132A 
grows progressively in nearly 100% of naive mice depleted 
of CD6+ cells (Ward et al., 1990). In addition to indicating 
an anti-tumor potential for Thl ceils, these experiments 
suggested that the 6132A antigen was released from a 
growing tumor and gained access to antigen-presenting 
cells (APCs) in the absence of adjuvant. 
Purification of an Antigen from 6132A Cells 
Fractionated lysates of 6132A PRO cells were tested for 
antigenicity by coculturing them with T cell hybridoma 
479H-60 and C3H spleen cells as a source of APCs, and 
then assaying the supernatant for the presence of IL-2. 
We took advantage of the observation that spleen cells are 
capable of endocytosing and presenting proteins bound to 
nitrocellulose (Young and Lamb, 1966). The 6132A anti- 
gen was found in the nuclear fraction of disrupted cells 
and could be solubilized with 2 M but not 0.4 M NaCl 
(Figure 5A). High salt nuclear extracts were fractionated 
by reverse-phase high pressure liquid chromatography 
(RP-HPLC) and sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE); antigenic activity was 
eluted with 40%-450/o acetonitrile and appeared to reside 
in a protein of molecular mass 20-22 kDa (Figures 58 and 
5C). Based on these findings, we used these techniques 
in the following sequence to purify the protein for amino 
acid sequencing: isolation of the nuclear fraction, preex- 
traction with 0.4 M NaCl (discarded), extraction with 2 M 
NaCI, RP-HPLC, and SDS-PAGE of antigenic HPLCfrac- 
tions. 
Identification of Ribosomal Protein L9 
as the 6132A Tumor Antigen 
The amino acid sequence of a tryptic fragment of the puri- 
fied protein was obtained (DFNHINVELSHLGK) and was 
found to be nearly identical to amino acids 37-50 of ribo- 
somal proteins L9 from both rat and human (DFNHIN- 
VELSLLGK; Suzuki et al., 1990; Hori et al., 1993). Indeed, 
antigenic activity was found at a high level in ribosomes 
isolated from 6132A PRO cells, and could be purified by 
the same techniques used to isolate it from the nuclear 
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Figure2. Antigen from 6132A PRO Is Recognized in Association 
with I-E’ 
(A) I-El restriction of an antM132A PRO T cell clone. Clone C47-10 
was incubated with C3H spleen cells and 3 x 105 cell equivalents per 
ml of dead 6132A PRO cells, with or without different amounts of 
culture supernatants containing MAb W-2-16 (anti-l-A9 or 14448 
(anti-W). Clone J6.19, which recognizes ovalbumin in association 
with I-AL, was incubated with C3H spleen cells and 800 uglml oval- 
bumin, with or without antibodies as above. The amount of stimulation 
was measured by thymidine incorporation assay. Error bars show the 
SEM of triplicate wells; errors less than 1000 cpm (C47-10) or less 
than 500 cpm (J6.19) are not shown. Thymidine incorporation by all 
of the other 6132%specific clones shown in Table 1 was similarly 
inhibited by anti-l-EL antibody. 
(B) I-E”restriction oftheantMl32A PROTcell hybridoma. Tcell hybrid- 
oma 479H-60 was incubated with different numbers of cell equivalents 
per ml of dead 6132A PRO cells and with L cells transfected to express 
either IAL (MT56.1.4) or I-EL (DcEKH1.7) as APCs. T cell hybridoma 
3A9, recognizing HEL associated with I-AL, was incubated with differ- 
ent numbers of micrograms per milliliters of HEL and the same APCs. 
IL-2 released into supernatants was measured. Error bars show the 
SEM of triplicate wells; errors less than 0.01 are not shown. Neither 
hybridoma secreted detectable IL-2 in response to the other antigen 
(data not shown). 
(C) Lysis of l-EL+ 6132A PRO cells by a CD4+ anti-6132A T cell clone. 
Transfectants of 6132A PRO expressing (TR2.34, closed circle; 
TR2.38, closed square) or not expressing (TR2.8, open circle) I-Ek 
were tested for sensitivity to lysis by clone C47-9 in a 4.5 hr %r-release 
assay. 
fraction (Figures 5D-5F). Because the nucleotide se- coding region of rat L9 and used them to amplify, from 
quences of the rat and human L9 coding sequences are cDNA from 8132A PRO, a fragment of about 600 bp, the 
91.5% identical (Hori et al., 1993), we reasoned that the expected size of the L9 coding sequence plus primers. 
mouse sequence should also be very similar to that of Using restriction enzyme sites incorporated in the PCR 
the rat. We designed primers for the polymerase chain primers, this fragment was cloned into pCA, a bacterial 
reaction (PCR) based on the 5’ and 3’ sequences of the plasmid vector allowing inducible expression of cloned 
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Figure 3. Chloroquine Blocks Presentation of Antigen from 6132A 
PRO Cells 
Spleen cells were treated with chloroquine, pulsed with antigen, and 
fixed with paraformaldehyde, as described in Experimental Proce- 
dures. T cell hybridomas recognizing 6132A (479H-60, top) or HEL 
(3A9, middle) were added, and 24 hr supernatants were tested for 
IL-2. Antigens were 2 x W/ml dead 6132A PRO cells, 1 mglml HEL, 
or 0.1 mg/ml HEL digested with trypsin (HEL-pep). The bottom panel 
shows that cells treated with chloroquine and fixed were still capable 
of presenting peptide antigen to 3A9, but were incapable of presenting 
intact HEL or 6132A antigen to the appropriate hybridoma. Error bars 
show the SEM of triplicate wells; errors less than 0.01 are not shown. 
genes as fusion proteins linked to Staphylococcal protein 
A encoded by the plasmid (Buelow et al., 1992). Lysates 
of recombinant bacteria stimulated 6132A-specific clones 
and hybridoma479H-60 at a high level, but a control lysate 
was also slightly stimulatoty (data not shown). To reduce 
this background stimulation, fusion proteins were partially 
purified from lysates by SDS-PAGE. Bands found in the 
recombinant lysate and not in the control l&ate stimulated 
a 6132Aspecific clone but not a 1591 -specific clone (Fig- 
ure S), strongly suggesting that L9 encoded the 6132A 
antigen. 
Sequencing of L9 cDNA 
The 5’ and 3’ rat L9 primers were used to amplify, by re- 
verse transcription (RT)-PCR, L9 coding sequences from 
RNA from 6132A PRO and from autologous fibroblasts 
(6132 HLF). Fragments of about 600 bp were cloned into 
several vectors, and these templates were used for DNA 
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Figure 4. Antigen-Specific Inhibition of Tumor Growth by CDQ Clones 
in SCID Mice 
C3H SCID mice, unmodified (open circle) orgiven intraperitoneal injec- 
tions of 4-5 x IO’ clones recognizing 6132A (C47-17, closed circle) 
or 1591 (C45-13, open triangle) received subcutaneous injections of 
3 x IO6 PRO4L cells and either lo5 6132A PRO or 10’ 6132A RE 
cells, on opposite flanks. Measurements at 21-24 days after challenge 
were pooled from three experiments that produced similar results de- 
spite slightly different conditions. The first experiment included four 
mice receiving C47-17, three receiving C45-13, and three untreated, 
all challenged with 6132A PRO. The second experiment had four mice 
each with clones and two without, but half of each group received 
6132A RE instead of 6132A PRO. The third experiment included four 
mice with C47-17 and three each untreated or with C45-13; an addi- 
tional injection of clones was given 7 days after the first. Statistics were 
calculated for individual experiments using Students t tests. Sizes of 
6132A PRO were significantly smaller in mice treated with C47-17 in 
experiments one and three (p < 0.03; p < 0.02) and sizes of PRO4L 
were significantly smaller in mice treated with C45-13 in all experi- 
ments (p < 0.005; p < 0.005; p < 0.05). Each p value is the larger of 
the two calculated by comparing the experimental group with the two 
control groups. Results for growth of 6132A RE and PRO in experiment 
two were similar to those in the other experiments, but differences 
between these small groups were not significant. 
sequencing. We were able to obtain sequences corre- 
sponding to nucleotides 36-556 of the rat and human L9 
coding regions (Figure 7). The 6132 HLF(wild-type mouse) 
sequence differed from that of the rat at 29 nt, but only 
one of these alterations should result in an amino acid 
change, the conservative shift A~p~~-Glu. The 6132A 
PRO (tumor) sequence differed from the wild-type mouse 
sequence at a single nucleotide: A instead of T at position 
140. The corresponding predicted amino acid sequence 
contained histidine instead of leucine at position 47; this 
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Figure 5. Purification of an Antigen from Nuclei or Ftibosomes from 
6132A PRO Cells 
(A) Hybridomastimulation assay of subcellular fractions of 6132A PRO 
cells. Whole cell lysate (closed circle), nuclei (open circle), 0.4 M NaCl 
nuclear extract (open square), and 2 M NaCl (post-O.4 M NaCI) nuclear 
extract (closed triangle) were tested for stimulation of IL-2 release from 
T cell hybridoma 479H-60. Error bars show the range of duplicate 
wells; errors less than 0.02 are not shown. 
(6) Hybridoma stimulation assay of RP-HPLC fractions. A 2 M NaCl 
nuclear extract of 6132A PRO cells (1.3 x lOa cell equivalents) was 
injected onto a C4 column in 20% acetonitrile, 0.1% TFA in five ali- 
quots. Materialelutingduringagradientof35%-45% acetonitrile(min- 
utes 10-50; left axis, solid line) was collected. Fractions (1 ml each) 
at minutes 31-45 were dried and resolubilized in urea-Tris-P-ME, and 
10% of each was blotted onto nitrocellulose to test for stimulation of 
IL-2 release from T cell hybridoma 479H-60 (closed circle, right axis, 
dotted line). 
(C) Hybridoma stimulation assay (T cell immunoblot) of material sepa- 
rated by SDS-PAGE. A 2 M NaCl nuclear extract of 6132A PRO cells 
(4.6 x 10’ cell equivalents) was separated by SDS-PAGE in a Tris- 
0.25 - 
Time (minutes) 
0.6 
A 
3x103 104 3x104 105 3x105 106 
Cell Equivalents per ml 
tricine gel system. Proteins were electroblotted onto nitrocellulose, 
and 4 mm wide strips were cut out and incubated with T cell hybridoma 
479H-60. Error bars show the range of duplicate wells; errors less 
than 0.01 are not shown. Arrows indicate the approximate positions 
of prestained molecular weight markers. 
(D) Crude ribosomes were prepared from 6132A PRO cells as the 
dense component of the deoxycholate-treated postnuclear superna- 
tant of ceils disrupted with NP-40, and were tested for stimulation of 
IL-2 release from T cell hybridoma479H-60. Error bars show the range 
of duplicate wells; errors less than 0.02 are not shown. 
(E) Crude ribosomes (2.1 x IQ cell equivalents) were separated by 
RP-HPLC and fractions collected and assayed as in (B). 
(F) The remaining 90% of HPLC fractions 35-45 assayed in (E) were 
separated by SDS-PAGE in Tris-tricine. Proteins were electroblotted 
onto nitrocellulose and stained with Ponceau S. A prominent band of 
the expected size (arrow, right) appears in the antigenic fraction 44 
(circled; see [El); the positions of prestained molecularweight markers 
(mw) are shown by the arrows at the left. No hybridoma stimulation 
assay was performed. 
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Figure 5 
histidine had already been seen by amino acid sequencing 
of a tryptic peptide (see above). Six HLF L9 cDNA clones 
from two PCR reactions all featured T at position 140; 
five 6132A PRO cDNA clones from two PCR reactions all 
featured A at position 140. In addition, all three cDNA 
clones sequenced from a different tumor, 61328, which 
originated in the same mouse, contained the wild-type T 
at position 140. 
Two other nucleotide differences, one among the HLF 
and one among the 6132A PRO cDNAs, were found only 
in individual isolates; thus, these mutations are likely to 
have occurred during PCR amplification. RT-PCR of RNA 
from HLF, 6132A PRO, and 61328 also amplified, in addi- 
tion to the obvious L9 homolog, several closely related 
sequences (data not shown). We have not investigated 
these sequences further, and we cannot rule out the possi- 
bility that they were amplified from contaminating genomic 
DNA rather than from mRNA. 
Use of Synthetic Peptides to Define 
the Antigenic Sequence 
The results of DNAsequencing suggested that the antigen 
from 6132A PRO cells was a mutant ribosomal protein L9 
containing a histidine residue at position 47. To test this 
idea, we synthesized peptides of 25 residues centered 
on position 47 and containing either histidine (6132A-L9p: 
NH*-LRRDFNHINVELSHLGKKKKRLRVD-CONH2) or leu- 
tine (Norm-L9p: NH*-LRRDFNHINVELSLLGKKKKRLRVD- 
CONH?) at that position. The mutant peptide stimulated 
release of IL-2 from T cell hybridoma 479H-60 over lOOO- 
fold more effectively than did the normal peptide (Figure 
8A). All of the 6132A-specific clones listed in Table 1 were 
highly activated by 6132A-L9p and less so by Norm-L9p; 
the 1591 -specific clone C45-13 did not increase DNA syn- 
thesis in response to either peptide (Figure 8B). 
Rejection of a Tumor Challenge by T Cells Induced 
by Immunization with the Synthetic 
Mutant Peptide 
Immunization of mice with the mutant L9 peptide (6132- 
L9p) emulsified in CFA induced lymph node cells that pro- 
liferated in response to a lysate of 6132A PRO cells but 
not to a lysate of 1591 PR04L cells (Figure 9A). Lymph 
node cells from mice immunized with the same amount 
of normal L9 peptide (Norm-L9p) did not increase DNA 
synthesis in response to either tumor cell lysate (data not 
shown). Cells generated by immunization with the mutant 
peptide and restimulation in vitro with 6132A PRO lysate 
caused regression of 6132A PRO in SCID mice but ap- 
peared to have no effect on the growth of 1591 PR04L 
(Figure 9B). Thus, immunization with the mutant L9 pep- 
tide induced lymph node cells capable of antigen-specific 
tumor rejection. 
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Figure 6. Ribosomal Protein L9 from 6132A PRO Expressed in Sac- 
teria Stimulates T Cells Specific for 6132A 
E. coli strain TGl was transformed with the plasmid vector pCA or 
with pCA ligated to the L9 coding sequence amplified from 6132A 
PRO cells by PCR (pCAIL9). Bacterial lysates were solubilized with 
urea, separated by SDS-PAGE, and the proteins transferred to nitro- 
cellulose. Prominent bands found only in the lysate of recombinant 
bacteria (pCAIL9 46 and pCAIL9 34) were cut out and incubated with 
clones specific for 1591 (C45-13) or 6132A (C47-17), as were the corre- 
sponding regions from the electrophoresed control lysate (pCA 46 and 
pCA 34). A band appearing only in the control pCA lysate and of the 
predicted size of protein A did not stimulate the clones (data not 
shown). 
Discussion 
We have isolated CD4+ T cells that recognize a unique 
antigen made by the UV-induced skin cancer 6132A, and 
we have used these T cells to identify this antigen at the 
molecular level. A single amino acid substitution in mouse 
ribosomal protein L9 appears to be the source of antigenic- 
ity, which provides a good explanation for the apparently 
unique expression of this determinant on 6132A but not 
other UV-induced murine tumors. The amino acid substitu- 
tion of histidine for leucine at position 140 is caused by 
a single nucleotide change, thymidine to adenosine at po- 
sition 140. Since this difference was the only one found 
comparing L9 cDNA from 6132A PRO with those from 
control tissues from the mouse of tumor origin, it is likely 
to be the result of somatic mutation. This assertion is sup- 
ported by the finding that the DNA change is within a string 
of T and C residues; pyrimidine dimers, which can lead 
to point mutations, are commonly produced in such se- 
quences by UV irradiation (Brash and Haseltine, 1982; 
Lebkowski et al., 1985). However, we cannot exclude the 
possibility that this gene exists in the normal mouse ge- 
nome without sequencing L9 genomic sequences; since 
there are 20-23 LS-related sequences in the rat (Suzuki 
et al., 1990), this task is impractical without knowing which 
Rat GmCTGAGAAGGG*CCGTCCAGCI\GCCTGACGAAn;A HLF --G------------- 
PRO --(+------------ 
mm v s E K G 
Figure 7. Sequences of L9 cDNAs from 6132A PRO and Autologous 
Fibroblasts 
Top line (Rat): published nucleotide sequence of cDNA encoding rat 
ribosomal protein L9 (Suzuki et al., 1990). Second line (HLF): consen- 
sus sequence of L9 PCR products, amplified from nontransformed 
autologous fibroblasts using primers corresponding to rat 5’ and 3’ 
sequences. Third line (PRO): consensus sequenceof L9 PCR products 
amplified from 6132A PRO cells. Fourth line (mL9): deduced partial 
amino acid sequence of mouse ribosomal protein L9. The only amino 
acid difference between normal mouse and rat L9 proteins among 
amino acids 13-165 is at position 17, which is glutamate in mouse 
(underlined) and aspartate in rat. The only nucleotide difference be- 
tween normal mouse and tumor cDNA among positions 36-556 is at 
position 140; this substitution encodes a histidine rather than a leucine 
at amino acid 47 (underlined). 
gene is transcribed. Although we do not yet know whether 
the mutant L9 protein is responsible for rejection of 6132A 
by unimmunized mice, this antigen is likely to be an immu- 
nologically important target, since T cells recognizing it 
inhibit tumor growth in vivo and were derived from hosts 
immunized against cancer cells; mice immunized in this 
way show a life-long tumor-specific immunological resis- 
tance. 
Several observations and lines of reasoning are consis- 
tent with the idea that many unique tumor-specific anti- 
gens are mutant proteins. First, the physical and chemical 
carcinogens inducing tumors bearing unique antigens are 
mutagens (Weisburger and Williams, 1981), and treat- 
ment of cancer cells with a point mutagen has produced 
immunogenic mutant proteins (Lurquin et al., 1989; Sibille 
et al., 1990). Second, one would expect that random muta- 
tion of coding sequences would yield unique antigens. In 
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Figure 8. Antigenicity of Peptides Corresponding to Amino Acids 
34-58 of L9 Proteins from 8132A PRO and from Normal Ceils 
(A) Hybridomastimulation assay. Serial dilutionsof 8132A-L9p (closed 
circle) and Norm-L9p (open circle) were tested for stimulation of IL-2 
release from T cell hybridoma 479H-60. The dotted line shows the 
mean for cultures without peptides. Error bars show the SEM of tripli- 
cate samples; errors less than 0.03 are not shown. 
(B) Thymidine incorporation assay. T cell clones and spleen cells were 
incubated without antigen, with 3 x 105 cell equivalents per ml of 
tumor cell lysates (6132A PRO or PRO4L), or with 50 nglml of synthetic 
peptides representing mutant (6132-L9p) or normal (Norm-L9p) L9 se- 
quences. Error bars show the range of two values (No Ag, 6132A, 
PR04L) or SEM of three (6132-L9p, Norm-L9p); errors less than 300 
cpm are not shown. 
contrast, mutations leading to overexpression of otherwise 
normal proteins would be more likely to produce shared 
antigens Third, mutant proteins should, in general, be 
more immunogenic than normal but overexpressed pro- 
teins, because the latter are more likely to be perceived 
as “self”; consistent with this idea, unique antigens are 
usually strongly immunogenic. Despite these arguments, 
however, direct evidence supporting the mutational origin 
of unique tumor antigens recognized by T cells from hosts 
immunized against cancer cells has been lacking. This 
study provides such evidence. 
A peptide tumor antigen, associated with MHC class I 
and recognized by CD8’T cells, was recently isolated from 
a spontaneous murine lung cancer cell line (Mandelboim 
et al., 1994). This antigen was reported to be encoded 
by a mutant connexin 37 sequence. The T cells reactive 
toward this peptide appeared to recognize a second spon- 
taneous lung tumor as well, although it is not certain that 
the antigen on the second tumor is biochemically identi- 
cal to that on the first. This finding raises the possibility 
that mutant proteins can act as shared as well as unique 
antigens. 
There are precedents for association of peptides from 
ribosomal proteins with MHC class I molecules. A nonam- 
eric peptide from normal ribosomal protein L28 is one of 
the major peptides associated with the MHC class I allele 
HLA-67 on IG-2 lymphoblastoid cells (Jardetzky et al., 
1991) and a nonameric peptide from ribosomal protein 
L19 is one of the major peptides associated with the non- 
polymorphic MHC class lb molecule SQ7b (Joyce et al., 
1994). In addition, exposure of the murine mastocytoma 
cell line P815 to the point mutagen N-methyl-N’nitro-N- 
nitrosoguanidine (MNNG) in vitro resulted in a mutant ribo- 
somal protein L13a(Sibille et al., 1990; Chan et al., 1994) 
which was recognized in association with MHC class I by 
cytolytic T cells. Although the relevance of this antigen to 
naturally occurring tumor antigens is unknown, the discov- 
ery of two independent antigens derived from mutant ribo- 
somal proteins is consistent with the possibility that such 
proteins, when mutant, commonly become antigenic. One 
general characteristic of ribosomal proteins is their abun- 
dance, and the level of expression of an antigen by cancer 
cells can affect the induction of immunity (Ki.indig et al., 
1993; Koeppen et al., 1993a). Another common trait of 
ribosomal proteins is their association with nucleic acids. 
A variety of nucleic acid-binding proteins, including ribo- 
somal proteins, histones, and components of small nu- 
clear ribonucleoprotein particles, are frequent targets of 
autoantibodies found in patient6 with lupus erythematosus 
and other autoimmune diseases (for review see Naparstek 
and Plotz, 1993). It is possible that proteins that are highly 
basic, are complexed with nucleic acids, or are associated 
with any large macromolecular complex are especially 
easily taken up by APCs. 
Although little is known about the function of ribosomal 
protein L9, it is possible that mutation of certain ribosomal 
proteins contributes directly to the initiation or progression 
of some cancers. For example, a deficiency in the activity 
of apuriniclapyrimidinic (AP) endonuclease I is associated 
with one form of xeroderma pigmentosum, in which there 
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Figure 9. Induction of 61 SPA-Specific T Cells with a Synthetic Peptide 
(A) Mice were immunized with 6132A-L9p in CFA (5 ng per foot) and 
the draining lymph node cells cultured with different concentrations 
of lysed 6132A PRO (closed circle) or 1591 PR04L (open circle) cells. 
[3H]thymidine was added on day 5 and the cultures harvested on 
day 6. Error bars show the SEM of triplicate wells; errors less than 
200 cpm are not shown. The mean of wells without antigen is shown 
as a dotted line. Similar results were obtained using mice immunized 
is increased susceptibility to UV-induced skin cancers and 
other malignancies (Kuhnlein et al., 1976). This enzyme 
appears to be.identical to ribosomal protein S3 (S. Linn 
et al., submitted). In addition, the trk-2h oncogene encodes 
a fusion of the kinase domain of Trk with part of ribosomal 
protein L7 (Ziemiecki et al., 1999) and reduced transcrip 
tion of the gene for ribosomal protein S6 causes over- 
growth of the hematopoietic system in Drosophila (Stewart 
and Denell, 1993). Our results have confirmed that ribo- 
somal protein L9 is highly conserved in evolution (Suzuki 
et al., 1990; Hori et al., 1993) and it may be necessary 
for cell survival and high fidelity protein biosynthesis in 
normal cells. Furthermore, the mutant L9 may also be 
required for the survival, and therefore the malignancy, 
of 6132A PRO cells, since we did not find any transcripts 
for the normal counterpart, nor have we found tumor vari- 
ants that have lost expression of this mutant protein. The 
success of immunotherapy may depend on the existence 
of antigens that cannot be easily lost by cancer cells. 
The approach we have developed may be useful for 
identifying other unique antigens, which are frequently 
present on tumors caused by chemical or physical carcino- 
gens. Purification of intact proteins should, in general, be 
easier than purification of peptides eluted from MHC mole- 
cules, because of the smaller numbers of cells required 
and the possibility of fractionating material on the basis 
of size. Intact proteins might also be assayed for stimula- 
tion of tumor-specific CD6+ T cells by hydrolyzing the pro- 
teins briefly with alkali (Gavin et al., 1993). It is presently 
unclear whether our approach of protein purification and 
T cell immunoblotting, or elution of peptides from MHC 
molecules (Cox et al., 1994; Mandelboim et al., 1994) or 
expression cloning in eukaryotic cells (Van der Bruggen 
et al., 1991) or bacteria (Hickling et al., 1992) will be most 
useful for identifying tumor antigens. In any case, our 
method of using CD4+ tumor-specific T cell clones or hy- 
bridomas for identifying the genetic origins of tumor anti- 
gens may uncover novel mutant proteins in cancer cells 
that not only are important immunological target mole- 
cules, but also are important in the development and pro- 
gression of malignancy. 
Experimental Procedures 
Mice and Cell Lines 
Female C3HIHeN MTV and BALBlc mice were purchased from the 
Frederick Cancer Research Facility. Male and female C3H SCID mice 
were provided by J. Bluestone; they were bred at the University of 
Chicago from mice purchased from the Jackson Laboratory. The C3H 
with 2.5 ng peptide per foot. Lymph node cells from mice immunized 
with the same amount of normal L9 peptide (Norm-L9p) did not in- 
crease DNA synthesis in response to either tumor cell lysate (data not 
shown). 
(B) 6132A-specific cells were generated by immunizing mice with 
6132A-L9p (2.5 or 5 ng per foot) and restimulating the draining lymph 
node cells with lysed 6132A PRO cells. SCID mice, either untreated 
(open circle) or receiving 8-9 x lo6 6132A-specific cells intraperitonb 
ally (closed circle), were inoculated with IO5 6132A PRO cells and 
3 x 1 OS 1591 PR04L cells subcutaneously on opposite flanks. Tumor 
sizes 28 days after challenge are shown, pooled from two experiments, 
each with two mice per group. 
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tumors used were the spontaneous fibrosarcoma AG104A (Ward et 
al., 1989) and UV-induced skin tumors described previously: 6130, 
6132A, 6132B,6136,and6139B(Wardetal., 1969); 4102PR0,6132A 
PRO, 6134A PRO, and 61398 PRO (Ward et al., 1990); 1591 PR04L 
(Urban et al., 1962). 1591 TR-PRO (PR04L transfected with an alloge- 
neic MHC class I molecule; Koeppen, et al., 1993b), and 1591 RE3.5 
(Teng et al., 1991). These cell lines were maintained in MEM with 5%- 
10% fetal bovine serum (FBS), as were fibroblasts from the heart and 
lungsof the mouse in which 6132A and 61328 originated (6132 HLF). 
The 6132A tumor is part of a large tumor library (Ward et al., 1969) 
which is unique in that we have isolated autologous control cells from 
each mouse in which a tumor originated. Using these control cells, 
we can distinguish between somatic and germline mutations. Without 
such controls, some antigens found to be tumor specific (Philipps et 
al., 1965) may later be identified as products of polymorphic genes 
(Lee et al., 1966). Antigen-presenting L cell transfectants MT58.1.4 
(Ltk- cells transfected with I-A’ and genomic Ii; Peterson and Miller, 
1992) and DcEKHl.7 (DAP3 cells transfected with I-Ek and expressing 
endogenous genomic Ii) were gifts from J. Miller. T cell hybridoma 
3A9 (Allen and Unanue, 1984). recognizing hen egg lysozyme (HEL), 
and solutions of intact and trypsin-digested HEL were also gifts from 
J. Miller. CD4’ T cell clone J6.19, recognizing ovalbumin associated 
with I-AL (Wilde and Fitch, 1984) was a gift from F. Fitch, as was 
CTLL-2, responsive to IL-2 and IL4 (Gillis and Smith, 1977). BW5147 
(Goldsby et al., 1977) was a gift from J. Urban. 3A9, MT56.1.4, and 
DcEKH1.7 were maintained in DMEM supplemented with 10% FBS 
(Sigma or GIBCO), 2 mM glutamine (GIBCO), 0.1 mM nonessential 
amino acids (GIBCO), 10 mM HEPES (GIBCO) or 50 mM MOPS, 
5 x 10m5 M P-mercaptoethanol(2-ME), and penicillin and streptomycin 
(GIBCO); CTLL-2 was grown in the same medium plus 20-30 U per 
ml of recombinant human IL-2 (Cetus). BW5147 was grown in RPM1 
supplemented with 10% FBS, glutamine, nonessential amino acids, 
HEPES, 2-ME, penicillin and streptomycin, and 1 mM sodium pyruvate 
(GIBCO). 6132A PRO and 1591 TR-PRO cells were tested for contami- 
nation with mycoplasma by staining with Hoechst 33256, followed by 
fluorescence microscopy. 
Generatlon, Maintenance, and Analysis of CD4+ T Cells 
6132A PRO or 1591 TR-PRO cells were washed with MEM, resus- 
pended at a density of 8-13 x 10’ cells per ml in MEM, lysed by three 
cycles of freezing and thawing, and emulsified with an equal volume 
of CFA (Difco). About 0.05 ml of emulsion was injected into each hind 
foot of C3H mice. The popliteal lymph nodes were removed 7 or 6 
days later and the cells dispersed and cultured as follows: 2 x lo8 
lymph node cells, 4-6 x 1 O8 irradiated (20 Gy) syngeneic spleen cells, 
and antigen (see below) in a well of a 24well plate in 1.5 ml of DMEM 
supplemented with 0.4% fresh syngeneic mouse serum, glutamine, 
HEPES or MOPS, 2-ME, and penicillin and streptomycin at the same 
concentrations as above; sometimes, nonessential amino acids, nys- 
tatin (GIBCO), and gentamycin (GIBCO) were added at the same con- 
centrations as above. Antigens were different amounts of tumor cell 
lysates, which were routinely made at concentrations of 6 x 1 Or cells 
per ml and were stored at 4OC. After 7-11 days of culture, T cells 
were cloned by limiting dilution in 96well plates in the medium above 
supplemented with 13 U/ml of recombinant human IL-2. After cloning, 
cells were expanded and passaged in the same medium, but with 
10% FBS instead of 0.4% mouse serum; the usual amount of antigen 
added was 2 x IO5 cell equivalents per ml. Clone C45-13 was some- 
times grown in the presence of 400 U/ml of recombinant murine IFNy 
(Genentech), but its performancewas similar with or without this added 
cytokine. 
Expression of cell surface markers was assessed by flow cytometry 
(FACScan, Becton-Dickinson). The antibodies used were anti-L3T4(CD4) 
conjugated to phycoerythrin (Becton-Dickinson), anti-V86 conjugated 
to fluorescein isothiocyanate (FITC; PharMingen), and anti-V51 4-FITC 
(PharMingen). 
The specificity for antigen of T cell clones was assessed by thymi- 
dine incorporation assay. T cell clones were washed twice 9 or more 
days after the last restimulation with antigen to remove residual IL-2. 
then cultured as follows: lo5 T cells and about lo6 irradiated (20 Gy) 
syngeneic spleen cells, with or without a tumor cell lysate, in a well 
of a flat-bottomed 96-well tissue culture plate in 0.2 ml DMEM supple- 
mented as above but without IL-2. About 24 hr later, 1 uCi of PHjthymi- 
dine (Amersham) was added to each well, and about 24 hr after that, 
the cultures were harvested onto glass fiber filters using a PHD cell 
harvester (Cambridge Technology). Radioactivity was measured by 
liquid scintillation counting. For some experiments, culture superna- 
tants containing MAb 10-2-16 (anti-l-Ah; Oi et al., 1978) or 14448 
(anti-l-l?; Ozato et al., 1960) were added at the beginning of culture. 
For other experiments, antigen was added in the form of protein elec- 
troblotted onto nitrocellulose, which was removed just before adding 
[3H]thymidine. 
Supernatants for measurement of cytokines were obtained by incu- 
bating washed T cells at a concentration of I@ cells per ml in plates 
(24-well or 96well) coated with anti-CD3 MAb 2Cll (Leo et al., 1987) 
a gift from J. Bluestone. The 2Cll antibody was applied to wells either 
as culture supernatant or as a 10 ug/ml solution of affinity-purified 
antibody. Units of IL-2 and IL-4 were measured by adding dilutions of 
T cell supernatants to CTLL-2 cells in the presence of MAb blocking 
either IL4 (11 Bl I, a gift from F. Fitch; Ohara and Paul, 1985) or IL-2 
(S4B6, a gift from Ft. Coffman; Mosmann et al., 1986) and its receptor 
(3C7, a gift from F. Fitch; Ortega et al., 1984). IFNy was measured 
by enzyme-linked immunosorbent assay (ELISA) (Schreiber et al., 
1985) the reagents for which were provided by F. Fitch. TNF/LT was 
measured by cytolysis/cytostasis of the TNF-sensitive cell line 1591 
RE3.5 (Teng et al., 1991). 
Cytolysis was measured by 4-5 hr s’Cr-reIease assay (Urban et al., 
1982; Ward et al., 1989). The target cells had been transfected with 
DNAs encoding I-Ea and I-EfY (p&XV-Ea and pcEXV-EPk; Miller and 
Germain, 1986) and neomycin resistance (pSV2-neo). These plasmids 
were provided by J. Katz, A. Sant, and J. Miller. G418resistant cells 
expressing I-E’(binding to 14445) were enriched by magneticsorting 
using 14448 and Dynabeads (Dynal) and cloned by limiting dilution. 
Clones were analyzed for cell surface expression of I-E” by flow cytome- 
try, using 144-48 and goat anti-mouse IgG-FITC (HyClone). 6132A 
PRO and 1591 PR04L cells were also tested for expression of I-EL in 
this way, as well as for expression of I-A’ by staining with 10-2-16 and 
goat anti-mouse IgG-FITC. 
Generating CD4’ T cells by the methods above requires caution. 
Immunizing and restimulating with cells cultured in FBS seems to 
stimulate CD4+ cells recognizing FSS proteins, so that under these 
conditions, tumor-specificT cells may be found only when the immuniz- 
ing tumor has a strong antigen. Other investigators have reported 
similar domination of cultures by cells recognizing FBS proteins or 
bacterial collagenase used to digest tumors (Cohen et al., 1994). In 
addition, cell extracts contaminated with mycoplasma greatly stimu- 
late activation of lymph node cells during their initial passage, whether 
by mitogenic activity or by cross-reactivity with antigens in CFA. Both 
problems can be avoided by using tumors excised from SCID or nude 
mice as the sources of antigen (P. A. M., unpublished data). 
Generation and Analysis of T Cell Hybrldomas 
T cell clone C47-9 was fused, 3 days after stimulation with antigen 
and IL-2, to BW5147 using polyethylene glycol (Goldsby et al., 1977). 
Isolates resistant to hypoxanthine-aminopterin-thymidine (GIBCO) 
were tested for secretion of IL-2 in the presence of syngeneic spleen 
cells and lysates of 6132A PRO cells. Hybridoma 479H-60, which was 
used later to assess purification of an antigen from 6132A PRO lysates, 
was maintained in supplemented RPMI. The standard assay for IL-2 
secretion by this cell line or by T cell hybridoma 3A9 was performed 
by culturing about lo8 irradiated (20 Gy) syngeneic spleen cells in 0.1 
ml supplemented DMEM with 0.1 ml of confluent hybridoma culture 
in a well of a 96well plate. Antigen was added in the form of tumor 
cell lysate, fractionated extract, protein blotted onto nitrocellulose elec- 
trophoreticallyor by capillary action (Bio-Dot apparatus; Bio-Rad), pure 
protein, or synthetic peptide. After about 24 hr of culture, 0.1 ml of 
culture supernatant was removed and added to washed CTLLQ cells; 
about 24 hr later, 0.1 ml of supernatant was removed and discarded, 
and 0.02 ml of 3(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro- 
mide (MTT; 5 mglml) was added to each culture. The following day, 
0.1 ml of 10% SDS, 0.01 M HCI was added, and the day after that the 
absorbance at 570 nm minus the absorbance at 650 nm was measured 
using a V, kinetic microplate reader (Molecular Devices). This MTT 
assay (Mosmann, 1983) was used for quantitating bioassays for IL-2, 
IL-4, and TNFlLT as well (see above). For some assays, MT58.1.4 
and DcEKHl.7 were used instead of syngeneic spleen cells as APCs. 
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For assays involving chloroquine (Allen and Unanue, 1984) spleen 
cells were first treated for 15 min at room temperature with 0.1 mM 
chloroquine or with buffer. After antigens were added, the cells were 
incubated at 37OC for at least 2 hr. then washed, fixed with 1% para- 
formaldehyde in HanKs balanced salt solution, washed, incubated at 
37OC for 1 hr to release residual fixative, and washed again before 
incubating with T cell hybridomas. 
Protein Purification 
Nuclei were prepared from cultured tumor cells by disrupting the cells 
twice with 1% Triton X-100 in RSBI (10 mM Tris-HCI, 10 mM NaCI, 
3 mM MgCln, 300 &ml leupeptin, 300 uglml aprotinin, 40 ug/ml phe- 
nylmethylsulfonyl fluoride [pH 7.51) for 1 hr at 4°C and recovering the 
nuclei by centrifugation at 2000 x g. Nuclei were incubated twice with 
RSBI plus 0.4 M NaCl for 1 hr at 4OC, then once with RSBI plus 2 M 
NaCl overnight at 4OC. This last extraction was centrifuged at 
200,ooO x g for 2-3 hr and the supernatant retained. Ribosomes were 
prepared as described by others (Sallustio and Stanley, 1990). In brief, 
the supernatant of cells disrupted with Nonidet P-40 (NP-40) was 
treated with deoxycholate. then layered on a discontinuous sucrose 
gradient and centrifuged at 100,000 x g for 24 hr; the pellet, enriched 
in ribosomes, was saved and resuspended in 20 mM Tris-HCI (pH 
7.8) 5 mM magnesium acetate, 100 mM NH&I, 1 mM dithiothreitol, 
0.2 M sucrose. Bacterial lysates prepared by digestion and disruption 
with lysozyme, deoxycholate, and DNAase (Sambrook et al., 1989) 
were centrifuged at 10,000 x g for IO min, and the pellets solubilized 
with 8 M urea at 4OC overnight. 
To prepare a nuclear extract or ribosomal fraction for either RP- 
HPLC or SDS-PAGE, it was mixed with an equal volume of UT2 
(8 M urea, IO mM Tris-HCI [pH 8.5],2% 2-ME) and an equal volume 
of 3x SDS (12% (w/v) SDS, 150 mM Tris-HCI [pH 8.81. 15% (v/v) 
glycerol, 0.03% (w/v) bromophenol blue), with additional 2-ME added 
to a final concentration of 5% (v/v); this solution was then incubated 
at 37OC for 1 hr. This unorthodox combination of denaturants was 
used because it was theonlysolution we tried that seemed tosolubilize 
the antigenic activity consistently. In particular, we found that high 
salt nuclear extracts frequently precipitated in the 0.1% trifluoroacetic 
acid (TFA) used for chromatography. However, the sample that was 
eventually used to obtain amino acid sequence was not combined 
with UT2, 3 x SDS, or 2-ME before chromatography. 
RP-HPLC was performed on an IBM LC/9533 ternary gradient liquid 
chromatograph with a 4.8 mm x 25 cm C4 column (Vydac). All HPLC 
experiments were performed using water and acetonitrile (AcCN), both 
acidified with 0.1% (v/v) TFA, at a flow rate of 1 ml per minute; fractions 
of 1 min duration were collected. Routinely, a sample was loaded at 
20% AcCN in several aliquots of 1 ml each; after the final loading, 
the concentration of AcCN was increased to 35% using a linear gradi- 
ent over the first 10 min, then to 45% over the next 40 min; the sample 
that was used to obtain amino acid sequence was loaded at 35% 
AcCN and eluted, as above, with a 40 min linear gradient to 45% 
AcCN. Fractions were dried in a Speed Vat concentrator (Savant), 
resuspended in 40-80 ul of UT2, and placed at 4OC overnight before 
using. 
Antigen from 8132A PRO cells, whether from nuclei or HPLC frac- 
tions, was separated by SDS-PAGE using a Tris-tricine buffer system 
(Schagger and von Jagow, 1987). The resolving gel was 18.5% T, 3% 
C, and a spacer gel with 10% T, 3% C was usually included between 
the resolving and stacking gels. In addition, 10 mM dithiothreitol was 
included in the resolving and spacer gels, and 0.2% 2-ME was added to 
the cathode and anode buffers. For separating proteins from bacterial 
extracts, SDS-PAGE conditions according to Laemmli (1970) were 
used, with 12% acrylamide in the resolving gel. In either case, an 
HPLC fraction in UT2 or a bacterial lysate in 8 M urea was prepared 
for SDS-PAGE by adding one half volume 3 x SDS and 2-ME to 5% 
and incubating at 37OC for 1 hr. Separated proteins were transferred 
to nitrocellulose at 50-80 mA for 18-24 hr in 25 mM Tris, 192 mM 
glycine, 20% (v/v) methanol. For obtaining amino acid sequence, pro- 
teins were transferred to PVDF (Pro-Blott; Applied Biosystems) under 
the same conditions. Nitrocellulose and PVDF membranes were 
stained with Ponceau S. 
Protein Sequencing 
All steps were performed at the Harvard Microchemistry Facility. Pro- 
tein bound to PVDF was cleaved with trypsin and the fragments eluted 
and separated by RP-HPLC. A prominent peak was subjected to Ed- 
man degradation, yielding the sequence DFNHINVELSHLGK. 
PCR, DNA Cloning, and DNA Sequencing 
Oligonucleotides were purchased (Operon) that corresponded to the 
B’sense and 3’antisense sequences of the coding region of the cDNA 
for rat ribosomal protein L9, with a BamHl site attached to the 5’ end 
of the 5’ sense sequence and Xhol and EcoRl sites attached to the 
5’ end of the 3’ antisense sequence; the resulting oligonucleotides 
were 5’GTCGGATCCATGAAGACCATTCTCAGCAATCA and 5%TG- 
AATTCTCGAGGTCTCATTCGTCAGGCTG, respectively. These prim- 
ers were used to reverse-transcribe RNA from cultured cells and am- 
plify it by PCR. RNA was isolated from 8132A PRO, 8132 HLF, and 
81328 cells by the Trireagent method (Molecular Research Center). 
RNA was mixed with the 5’ and 3’ primers and MMLV reverse tran- 
scriptase (GIBCO BRL), and incubated at 38’C for 10 min; after incu- 
bating at 94OC for 5 min, Taq polymerase (Promega) was added, and 
40 cycles of PCR performed as follows: 1 min at 94OC; 2 min at 55OC; 
3 min at 72OC. Products were blunt-ended by an additional 10 min 
incubation at 72OC at the end of the PCR. All incubations were per- 
formed in a Perkin-Elmer Cetus 480 DNA thermal cycler. Double- 
stranded cDNA was also made from RNA from 8132A PRO cells; RNA 
isolated with RNAzol (CinnalBiotecz) was reverse-transcribed with 
M-MLV-RT using an oligo-dT primer, and the second DNA strand was 
synthesized with the Klenow fragment of Escherichia coli DNA poly- 
merase I (New England Biolabs). PCR products were either digested 
with Bamlil and Xhol and ligated into pCA (Buelow et al., 1992) or 
digested with BamHl and EcoRl and ligated into pBluescript II KS 
(Stratagene) or pCDNA3 (Invitrogen). Recombinant pCA plasrriids 
were electroporated (GenePulser; Bio-Rad) into E. coli strain TGl, and 
recombinant pBluescript and pCDNA3 plasmids were electroporated 
into E. coli strain TOPIOF’; bacteria containing plasmids were main- 
tained in 2x YT medium with 100 &ml carbenicillin. 
Plasmid DNA was prepared by standard small-scale techniques 
(Sambrook et al., 1989) with the inclusion of extractions with phenol, 
phenol/chloroform/isoamyl alcohol (25/24/l v/v/v), and chloroform/ 
isoamyl alcohol (24/I v/v). DNA sequencing by the dideoxy chain termi- 
nation method (Sanger st al., 1977) was performed with a Sequenase 
Version 2.0 kit (United States Biochemical) according to the instruc- 
tions of the manufacturer, using alkaline denaturation of plasmid DNA, 
either of the two L9 primers described above, and ?S-labeled dATP 
(Amersham). Two persistent compression artifacts at nucleotide posi- 
tions95-98and212-215were resolved bysequencing with dlTPusing 
the same procedure. 
Synthetic Peptides 
The following peptides were synthesized on an Applied Biosystems 
431A peptide synthesizer using t&c chemistry: NHTLRRDFNHIN- 
VELSHLGKKKKRLRVD-CONH? (8132-L9p) and NH?-LRRDFNHIN- 
VELSLLGKKKKRLRVDCONH2(Norm-L9p).Syntheticyieldswerecal- 
culated by quantitative ninhydrin tests of resin samples taken during 
synthesis; all steps showed >99% yield. Peptides were cleaved from 
the resin using anhydrous HF/p-cresollresin in a 10/1/l (v/v/w) mixture. 
After cleavage, peptides were extracted into 0.5% (w/v) ammonium 
bicarbonate and desalted by gel filtration chromatography using Seph- 
adex G-25 Superfine in a 95 x 2.8 cm column. Peptides were purified 
by RP-HPLC using the system, C4 column, and solvents described 
above. Samples in 0.1% TFA were loaded at 18% AcCN and eluted 
with a 90 min linear gradient to 28% AcCN; the Norm-L9p peptide 
eluted at 27-47 min in different runs, and the 8132-L9p peptide eluted 
at 14-24 min in different runs. The concentrations and compositions 
of HPLC-purified peptides were determined by amino acid analysis 
(Heinrikson and Meredith, 1984). Peptides were analyzed by fast atom 
bombardment mass spectrometr-y (University of Illinois at Chicago 
MAT 90 Mass Spectrometry Facility) to verify their identities. 
Tumor Challenge 
T cell clones were harvested 9 days after the last stimulation with 
antigen and 11-2, washed once with MEM, and injected intraperitone- 
ally into C3H SCID mice, 4-5 x IO’ cells per mouse. Immediately 
thereafter, each mouse received subcutaneous inoculations of 3 x 
IO5 PR04L cells and either 1 O5 8132A PRO or 10’8132A RE cells, on 
zytic Origin of a Unique Tumor Antigen 
opposite flanks. In one experiment, mice received a second injection of 
clones 7 days after the first. Tumors were measured twice per week 
starting on day 14 after challenge. The tumor sizes in cubic centimeters 
were calculated by dividing the product of the three maximum orthogo- 
nal diameters by two; this calculation approximates the formula for 
an ellipsoid, 
nabc 
6 
where a, b, and c are the three maximum orthogonal diameters, 
Short-term T cell lines were generated by immunizing mice with 
synthetic peptides emulsified in CFA (2.5 or 5 ng per foot) and culturing 
the lymph node cells with tumor cell lysates using the conditions de- 
scribed above for primary cultures. Cells used for thymidine incorpora- 
tion assays were transferred to 96-well plates and received PH]thymi- 
dine on day 5; cultures were harvested on day 6. Cells for use in 
vivo were harvested on day 9, washed once with MEM, and injected 
intraperitoneally into SCID mice (6-9 x 108 per mouse). SCID mice 
subsequently received 1056132A PRO cells and 3 x lo6 PRD4Lcells 
subcutaneously on opposite flanks. Tumors were measured and sizes 
calculated as above. 
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